Patents Assigned to Sitari Pharma, Inc.
  • Transglutaminase 2 (TG2) inhibitors
    Patent number: 12152026
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 26, 2024
    Assignee: Sitari Pharma, Inc.
    Inventors: David Campbell, Justin Chapman, Mui Cheung, Thomas R. Diraimondo, Sergio G. Duron
  • Transglutaminase 2 (TG2) inhibitors
    Patent number: 11548892
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: January 10, 2023
    Assignee: Sitari Pharma, Inc.
    Inventors: David Campbell, Justin Chapman, Thomas R. Diraimondo, Sergio G. Duron